Biotech Industry · global
Funding Challenges Amid the AI Drug Discovery Boom: BIX 2026 in Seoul Brings Together Biotech Companies from 35 Countries
From AI drug discovery to pharmaceutical manufacturing in space, Seoul’s biotech exhibition highlights expanding R&D frontiers. But as capital flows toward AI, the biotech industry also faces the practical challenge of sustaining lengthy validation processes.
AI is opening up possibilities for new drug development while adding another dimension of competition for biotech companies: investors’ capital and patience. BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), held in Seoul from October 28 to 30, brought drug discovery, next-generation therapies, investment, and mergers and acquisitions onto the same agenda, reflecting the funding questions the industry must address as it pursues technological breakthroughs.
The exhibition was hosted by the Korea Biotechnology Industry Organization (KoreaBIO) and organized by RX Korea at the COEX convention and exhibition center. News1 reported that the event brought together more than 300 companies from 35 countries; before the event, the organizers announced 600 booths, 30 conference sessions, and more than 90 speakers. These figures show the breadth of the platform for exchange, but they do not establish how many collaborations or investments it actually facilitated.
Funding pressure forms an important backdrop to the exhibition. According to News1, KoreaBIO Chairman Koh Han-seung said in his opening remarks that investment flows toward AI were making fundraising more difficult for the biotech industry. This industry assessment reveals AI’s dual role at the event: it is both a tool for drug development and another force competing for capital.
In biomedical applications, the central question for AI drug discovery is whether it can help researchers identify targets or candidate molecules worth testing from large volumes of data. However, the verifiable exhibition materials available for this event mainly listed topics and the scale of activities, without providing training data, comparative experiments, or clinical outcomes for specific platforms. The inclusion of AI as a conference topic therefore does not establish that it has improved the success rate of new drug development; model-generated predictions still require step-by-step testing through experiments and subsequent clinical studies.
The agenda also extended to brain-computer interfaces and pharmaceutical manufacturing in space. These topics indicate that the biotech industry is seeking new settings for R&D, but the organizers’ announcements did not specify the maturity, validation results, or market launch timelines of the relevant projects. Readers should distinguish the directions explored at the conference from medical advances already supported by empirical evidence.
Cross-border collaboration had more concrete arrangements. Canada was selected as this year’s country of honor, and the organizers announced a Canadian pavilion and participation by a delegation of approximately 30 biotech and healthcare companies; the event also arranged one-on-one business matchmaking. As discussions move toward joint R&D, the next assessable outcomes will be specific collaboration details, resource commitments, and validation plans, beyond participation figures alone.